Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 8/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036338 | 0.94 | AKR1C3 (0.40) | HSD17B10AKR1C3MTNR1BPPARDPPARA | |
| SCHEMBL6036245 | 0.88 | PPARD (0.42) | PPARDPPARAPPARGKDM4ELMNA | |
| SCHEMBL6036318 | 0.87 | PPARD (0.40) | HSD17B10AKR1C3MTNR1BPPARDPPARA | |
| SCHEMBL6034532 | 0.87 | PPARD (0.43) | PPARDPPARASMN1; SMN2PTGDR2 | |
| SCHEMBL6035776 | 0.87 | PPARD (0.39) | PPARDPPARAPTGDR2 | |
| SCHEMBL6036205 | 0.86 | RXRA (0.38) | HSD17B10AKR1C3PPARDPPARAPPARG | |
| SCHEMBL6254047 | 0.85 | CYP1A1 (0.38) | HSD17B10PPARDPPARAPPARGLIPE | |
| SCHEMBL6034671 | 0.85 | PPARD (0.42) | PPARDPPARAPPARGKDM4ELMNA | |
| SCHEMBL6035761 | 0.85 | HCRTR1 (0.39) | HSD17B10PPARDKDM4ELMNAMAPK1 | |
| SCHEMBL6036127 | 0.84 | PPARA (0.39) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | HSD17B10 204/4885AKR1C3 227/4885MTNR1B 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.